

University of Dundee

## Implementing criteria-based early switch/early discharge programmes

Nathwani, D.; Lawson, W.; Dryden, M.; Stephens, J.; Corman, S.; Solem, C.

*Published in:*  
Clinical Microbiology and Infection

*DOI:*  
[10.1016/j.cmi.2015.03.023](https://doi.org/10.1016/j.cmi.2015.03.023)

*Publication date:*  
2015

*Licence:*  
CC BY-NC-ND

*Document Version*  
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

*Citation for published version (APA):*  
Nathwani, D., Lawson, W., Dryden, M., Stephens, J., Corman, S., Solem, C., Li, J., Charbonneau, C., Baillon-Plot, N., Haider, S., & Eckmann, C. (2015). Implementing criteria-based early switch/early discharge programmes: a European perspective. *Clinical Microbiology and Infection*, 21 (Suppl. 2), S47-S55.  
<https://doi.org/10.1016/j.cmi.2015.03.023>

### General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

# Implementing criteria-based early switch/early discharge programmes: a European perspective

D. Nathwani<sup>1</sup>, W. Lawson<sup>2</sup>, M. Dryden<sup>3</sup>, J. Stephens<sup>4</sup>, S. Corman<sup>4</sup>, C. Solem<sup>4</sup>, J. Li<sup>5</sup>, C. Charbonneau<sup>6</sup>, N. Baillon-Plot<sup>6</sup>, S. Haider<sup>7</sup> and C. Eckmann<sup>8</sup>

1) Ninewells Hospital and Medical School, Dundee, 2) Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, 3) Hampshire Hospitals NHS Foundation Trust, Winchester, Hampshire, UK, 4) Pharmerit International, Bethesda, MD, 5) Pfizer Inc., San Diego, CA, USA, 6) Pfizer Inc., Paris, France, 7) Pfizer Inc., Groton, CT, USA and 8) Klinikum Peine, Academic Hospital of Medical University Hannover, Peine, Germany

## Abstract

Early switch (ES) from intravenous (IV) to oral antibiotic therapy programmes is increasingly included as a component of hospital antimicrobial stewardship initiatives that aim to optimize antimicrobial therapy while limiting toxicity and resistance. In terms of prioritizing the most cost-effective stewardship interventions, ES has been seen as a 'low-hanging fruit', which refers to selecting the most obtainable targets rather than confronting more complicated issues. Administration of highly bioavailable oral antibiotics should be considered for nearly all non-critically ill patients and has been recommended as an effective and safe strategy for over two decades. However, to accrue the most benefit from ES, it should be combined with an early discharge (ED) plan, protocol, or care pathway. Benefits of this combined approach include improved patient comfort and mobility, reduced incidence of IV-line-related adverse effects, reduced IV antimicrobial preparation time, decreased hospital stays, reduced antimicrobial purchasing and administration costs, decreased patient deconditioning, and shortened recovery times. Results from published studies document decreases in healthcare resource use and costs following implementation of ES programmes, which in most studies facilitate the opportunity for ED and ED programmes. Barriers to the implementation of these programmes include clinician misconceptions, practical considerations, organizational factors, and a striking lack of awareness of IV to oral switch guidance. These and other barriers will need to be addressed to maximize the effectiveness of ES and ED programmes. As national antimicrobial stewardship programmes dictate the inclusion of ES and ED programmes within healthcare facilities, programmes must be developed and success must be documented.

© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.

**Keywords:** Antibiotic stewardship, antibiotic switch, implementation, intravenous to oral switch, methicillin-resistant *Staphylococcus aureus*

**Original Submission:** 11 November 2014; **Revised Submission:** 18 March 2015; **Accepted:** 19 March 2015

Editor: J.-L. Mainardi

**Article published online:** 18 July 2015

**Corresponding author:** J. Stephens, Pharmerit International, 4350 East West Highway, Suite 430, Bethesda, MD 20814, USA  
E-mail: [jstephens@pharmerit.com](mailto:jstephens@pharmerit.com)

## Introduction

Intravenous (IV) antibiotics are typically prescribed for hospitalized patients with serious, often life-threatening, infections. Results from a European point prevalence survey in acute-care

hospitals showed that the majority of patients with hospital-acquired infections (70%) received IV antibiotic therapy, although the rate ranged from a low of 50% in Scotland and Wales (UK) and Sweden to a high of 90% in Greece and Romania [1]. The duration of IV antibiotic therapy and hospital stays also varied widely among European countries [2,3]. Results from a study evaluating the treatment of patients with methicillin-resistant *Staphylococcus aureus* (MRSA) complicated skin and soft-tissue infections (cSSTIs) showed that duration of IV antibiotic therapy ranged from a low of 10.1 days in the UK to a high of 18.6 days in Poland. Mean hospital length of stay

ranged from a low of 15.2 days in the UK to a high of 25.0 days in Portugal [2].

In many cases, patients remain hospitalized for the full duration of IV antibiotic therapy. Although outpatient parenteral antibiotic therapy (OPAT) may be an option to reduce length of stay for some patients, these programmes are much more suited to areas where protracted parenteral antibiotic treatment is required (e.g. in bone and joint infections) or the availability of an effective, well-tolerated oral agent is limited. Furthermore, these programmes are not uniformly available throughout Europe [4], and evidence suggests that many patients who require home antibiotic therapy can be treated with an oral agent at hospital discharge, particularly where the course of antibiotic therapy is not prolonged [5]. Additionally, the burden of OPAT for both the patient and medical professional can be high. Patients require a line *in situ* which increases their risk of IV-line-related infections and, depending on OPAT model (e.g. OPAT centre, hospital unit administration), transportation to an outpatient infusion centre [6]. The impact of emerging novel single-dose or two-dose infusion therapies on the need for such OPAT infrastructure remains to be seen.

With the availability of potent, highly bioavailable oral antibiotics, there is an opportunity to promote switching from IV to oral therapy earlier and potentially reduce length of stay as a result. The availability of potent, highly bioavailable agents such as oral quinolones, macrolides and cephalosporins over the last two decades has transformed our ability to safely and effectively manage patients with a range of infections [7]. However, conversion from IV glycopeptides to oral therapy when treating serious, resistant Gram-positive infections remained a challenge until the introduction of linezolid in the early part of the last decade [2].

In this narrative review we discuss from a hospital standpoint the evidence to support the criteria for early switch (ES) and early discharge (ED), the value of these clinical programmes from a European perspective, and their implementation.

### Early switch/early discharge criteria: defined

Many hospitals are including ES and ED criteria as part of their antimicrobial stewardship programmes. Antimicrobial stewardship is defined as

“coordinated interventions designed to improve and measure the appropriate use of antimicrobial agents by promoting the selection of the optimal antimicrobial drug regimen including dosing, duration of therapy, and route of administrations. The major objectives of antimicrobial stewardship are to achieve best clinical outcomes related

to antimicrobial use while minimizing toxicity and other adverse events, thereby limiting the selective pressure on bacterial populations that drives the emergence of antimicrobial-resistant strains. Antimicrobial stewardship may also reduce excessive costs attributable to suboptimal antimicrobial use” [8].

Such stewardship programmes aim to promote the appropriate use of antibiotics through the use of standards and guidelines, education, communication and audit [9]. Early switch programmes focus on optimizing drug regimens and should be used in conjunction with other stewardship programmes that focus on minimizing antibiotic resistance.

Although criteria to use in ES programmes for patients with community-acquired pneumonia are provided in national guidelines [10,11], guidance for patients with other types of infections is less clearly defined. Numerous criteria were evaluated in studies evaluating ES and ED programmes in patients with various types of infections including lower respiratory tract infections, urinary tract infections, SSTIs, intra-abdominal infections (Table 1) [7,9,12–25]. Most programmes assessed ES and ED eligibility 2–4 days following initiation of IV antibiotic therapy. Typically at this time, culture and sensitivity results are available and the decision to continue or change treatment course can be made. Intravenous antibiotic therapy is only recommended for patients who are severely ill, are unable to tolerate oral antibiotic therapy, or need antimicrobial coverage or tissue penetration not obtainable with oral antibiotic therapy [26].

Intravenous to oral switch programmes are described in detail in the medical literature [9,12,14,16,17,19–21,23,24,27]. Although various criteria are included in these programmes, in general, criteria can be divided into those that assess available oral therapies, the patient's clinical status, and the patient's ability to adequately absorb orally administered therapy. Examples of IV antibiotics that have an oral equivalent include many penicillins, fluoroquinolones and linezolid. Examples of

**TABLE 1.** Criteria used to determine patient eligibility for intravenous to oral antimicrobial switch therapy

Criteria
Temperature <38°C or >36°C for 24–48 h; normalizing body temperature; afebrile for at least 8–24 h [5,9,12,14,16–18,20,21,23,25]
No unexplained tachycardia, haemodynamic instability [7,9,14,16,21,23,25]
Clinical improvement, no clinical indication for intravenous therapy [5,7,9,12,17–20,23,25]
Oral fluids/food tolerated, no reason to believe oral absorption of antimicrobials may be poor; may be by nasogastric/gastric feeding tube [5,7,9,12,14–20,22,23,25]
Improving white blood cell count [5,9,12,14,16,17,20,23,25]
Improving C-reactive protein [5,9]
Suitable oral antimicrobial therapy [9,12,23,24,33]
No surgery scheduled within next 24–36 h [16,25]

**TABLE 2.** Patients with methicillin-resistant *Staphylococcus aureus* complicated skin and soft-tissue infections (n = 1502) meeting early switch criteria before intravenous discontinuation

Early switch criteria <sup>a</sup>	Patients		Days from start of IV antibiotic therapy to meeting criteria
	n	%	Median (Range)
Stable clinical infection	663	44.1	7.0 (0–98)
Afebrile/temperature <38°C for 24 h	839	55.9	5.0 (0–98)
White cell count normalizing (>4 × 10 <sup>9</sup> but <12 × 10 <sup>9</sup> cells/L)	734	48.9	7.0 (0–98)
No unexplained tachycardia	789	52.5	4.0 (0–98)
Systolic blood pressure ≥100 mmHg	815	54.3	3.0 (0–98)
Tolerates oral fluids/diet and able to take oral medication with no gastrointestinal absorption problems	804	53.5	3.0 (0–98)
Available bacteriology for MRSA cSSTIs sensitive to oral antibiotic treatment	970	64.6	2.0 (0–43)
Available bacteriology for MRSA cSSTIs sensitive to OPAT antibiotic treatment	1043	69.4	2.0 (0–43)
No surgery scheduled for next 36 h	530	35.3	4.0 (0–98)
No requirement for IV line except IV antibiotic therapy	465	31.0	4.0 (0–45)

cSSTI, complicated skin and soft-tissue infection; IV, intravenous; MRSA, methicillin-resistant *Staphylococcus aureus*; OPAT, outpatient parenteral antimicrobial therapy.

<sup>a</sup>Criteria must be met before actual MRSA active IV antibiotic discontinuation.

criteria used to assess a patient's clinical status include temperature, white blood cell count and C-reactive protein as well as general overall clinical improvement. Examples of criteria used to assess a patient's ability to tolerate oral therapy include the ability to tolerate oral food or fluids and no reason to believe that oral therapy will be poorly absorbed.

We evaluated the likelihood and timing of meeting standard ES and ED criteria in a chart review study that captured data on 1502 randomly selected patients with MRSA cSSTI in 12 European countries [2,25]. Data were obtained from hospital records of patients aged 18 years or older who were hospitalized with a documented MRSA cSSTI between 1 July 2010 and 30 June 2011 and discharged alive by 31 July 2011. Study investigators determined whether patients met each ES and ED criterion before discontinuation of IV therapy (either switching from IV to oral antibiotics or discharge) and discharge, respectively, and the number of days from cSSTI diagnosis to

meeting criteria. Results of the evaluation are shown in Tables 2 and 3. Less than half of patients were identified as having a normalizing white blood cell count or stable clinical infection before discontinuation of IV therapy, with a median of 7 days from initiation of IV therapy to meeting these criteria. Patients were more likely to be afebrile, without tachycardia or hypotension, and to tolerate oral fluids/diet before discontinuation of IV therapy, and met these criteria earlier. With respect to early discharge criteria, over two-thirds of patients had stable clinical infections and improving white blood cell counts before discharge, but the median time to meeting these criteria (9 days) was longer than any other. Patients had other reasons to be hospitalized for a median of 8 days after cSSTI diagnosis, and less than half of patients met this criterion before discharge. Hence, it appears that the physician's assessment of clinical improvement and normalizing white blood cell counts would be important determinants of length of IV therapy and hospital stay

**TABLE 3.** Patients with methicillin-resistant *Staphylococcus aureus* complicated skin and soft-tissue infections (n = 1502) meeting early discharge criteria before actual discharge

Early discharge criteria	Patients		Days from diagnosis to meeting criteria
	n	%	Median (range)
No other reason to stay in the hospital except infection management	716	47.7	8.0 (0–122)
Stable mental status	796	50.3	2.0 (0–122)
Stable comorbid illness	755	50.3	4.0 (0–269)
Stable social situation	709	47.2	1.0 (0–122)
Stable clinical infection	1004	66.8	9.0 (0–138)
Afebrile/temperature <38°C for 24 h	1091	72.6	6.0 (0–138)
White cell count normalizing (>4 × 10 <sup>9</sup> but <12 × 10 <sup>9</sup> cells/L)	1032	68.7	8.0 (0–138)
No unexplained tachycardia	1007	67.0	5.0 (0–138)
Systolic blood pressure ≥100 mmHg	1028	68.4	4.0 (0–138)
Tolerates oral fluids/diet and able to take oral meds with no gastrointestinal absorption problems	1043	69.4	4.0 (0–138)
Available bacteriology for MRSA cSSTIs sensitive to oral antibiotic treatment	1101	73.3	2.0 (0–94)
Available bacteriology for MRSA cSSTIs sensitive to OPAT antibiotic treatment	1157	77.0	2.0 (0–94)
No surgery scheduled for next 36 h	658	43.8	5.0 (0–94)
No requirement for IV line except IV antibiotic therapy	626	41.7	6.0 (0–77)

if these criteria were applied prospectively. This finding is consistent with other studies, which suggest that the most common reason for not switching patients from IV to oral therapy is lack of clinical improvement [9,19].

## Benefits of ES and ED programmes

In terms of prioritizing the most cost-effective stewardship interventions, ES has been seen as a 'low-hanging fruit', which in reference to stewardship, refers to selecting the most obtainable targets rather than confronting more complicated management issues [28]. These strategies require fewer resources and less effort than other stewardship activities; however, they are applicable to a variety of healthcare settings, including limited-resource hospitals, and have demonstrated significant financial savings.

The goals of an ES and ED programme are to decrease both the duration of IV antimicrobial therapy and the length of hospitalization while maintaining equivalent effectiveness. Benefits of ES programmes that facilitate switching from IV to oral antimicrobial therapy include the following: improved patient comfort and mobility [5,17], reduced incidence of IV-line related adverse effects such as catheter-related bacteraemia and phlebitis [5,16,29], reduced nursing or pharmacy time spent preparing IV antimicrobials [5,17,30], decreased hospital length of stay [2,5,17,18,20,24,29,31] and reduced antimicrobial purchasing and administration costs [17,24]. Additionally, when clinical outcomes are equivalent, patients prefer oral therapy to IV therapy [32]. Benefits of ES followed by ED programmes include a lower risk of line-related infections [29], less patient deconditioning [5,23], and a shorter recovery time [23].

The benefits of ES programmes are well recognized in patients with community-acquired pneumonia. Guidelines for IV to oral switch therapy in patients with community-acquired pneumonia are included in national guidelines published by the British Thoracic Society [10] and the Infectious Diseases Society of America/American Thoracic Society [11]; the latter additionally includes criteria for ED. The actual or potential benefits of ES and ED programmes were demonstrated in numerous studies enrolling patients with various types of infections including those caused by bacteria and fungi [7,9,12–25,29,33]. Indeed, in children with pyelonephritis early IV to oral switch was deemed non-inferior to IV therapy only, thereby providing further evidence to support this intervention [34].

## Impact on healthcare resource use

Results from a 2003 Canadian study suggested a potential decrease in both IV treatment and hospitalization length for

patients hospitalized with an MRSA SSTI and treated with vancomycin [15]. Study results showed the potential for a saving of 14.5 IV-therapy-days for patients who met ES criteria, had they been switched to a suitable oral agent. The most frequently cited reason for not switching to oral therapy was the lack of an effective oral treatment as the study was conducted before the availability of linezolid. Twelve years later, the significant potential for reduction in length of IV treatment and hospitalization has been identified for patients hospitalized with an MRSA cSSTI in Europe [25]. In this real-world study, 504 of the 1502 enrolled patients (33.6%) met ES and ED criteria. Administration of an oral therapy active against MRSA had the potential to decrease the IV therapy duration by  $6.0 \pm 5.5$  days and hospital length of stay by  $6.2 \pm 8.2$  days. Another study from the UK including 211 patients within the same disease context found that 29% of patients receiving at least 5 days of IV glycopeptide therapy were eligible for ES and ED, saving 649 inpatient days over a 6-month period. An additional 247 IV antibiotic therapy days were saved by patients meeting ES but not ED criteria [16].

Results from a study conducted in Norway, across a range of infections, showed a significant decrease in IV therapy duration and hospital length of stay following implementation of ES guidelines [24]. Unnecessary IV therapy decreased in duration from 3.4 to 1.4 days and hospital stay from 7.0 to 6.3 days following implementation of ES guidelines. Importantly, no difference in mortality, need to restart IV therapy, or readmission rate was found.

The impact of a three-step critical pathway among patients hospitalized with community-acquired pneumonia was evaluated in a randomized trial conducted in two tertiary care hospitals in Spain. Recommendations for early mobilization of patients, use of objective criteria for switching from IV to oral antibiotics, and specific criteria for hospital discharge were implemented using a printed checklist placed in the chart of patients randomized to the critical pathway arm, with the control group receiving usual care. Use of the critical pathway was associated with a 2-day reduction in median length of IV therapy and a 2-day reduction in length of stay, with no detriment to safety measured by adverse events, hospital readmission and mortality [29].

## Impact on costs

Costs appear to be decreased in patients switched from IV to oral therapy. In a UK-based study conducted in medical and surgical wards across five UK hospital trusts, it was estimated that an ES and ED programme could save £363 per patient in total costs, of which £32 was attributable to switching from IV to oral antibiotic therapy alone [31]. Additional savings from

shorter hospital stays was also reported. Application of ES and ED criteria retrospectively to patients with MRSA cSSTIs in a pan-European chart review study suggested potential savings of more than €2000 in bed-day costs per ED eligible patient [25].

Cost savings may be even greater if indirect costs for drug administration are included in calculations. In a Dutch study, the average time required for drug administration by volumetric pump, syringe pump, 'unaided' infusion bag, and direct IV injection represented between 11% and 53% of the total antibiotic therapy daily costs [30]. These indirect costs ranged from 13% to 113% of antibiotic acquisition costs. The cost to insert an IV catheter was not included in this cost calculation, but was estimated at €9.17. In a separate study of 694 patients with various infection types, application of an ES checklist was estimated to reduce nurse workload by 350 hours per year [19].

## Implementation

### Country-specific programmes

Many countries are starting to include IV to oral switch therapy initiatives as a component of their national antimicrobial stewardship programmes. However, antimicrobial stewardship programmes are not consistently used among European nations. Evidence from the European Society of Clinical Microbiology and Infectious Disease (ESCMID) Study Group for Antibiotic Policies (ESGAP) global survey of antimicrobial stewardship shows that 81% of European countries and 73% of European hospitals have antimicrobial stewardship standards; 66% of hospitals have antimicrobial stewardship programmes in place [35]. Various strategies are used by these stewardship programmes, with approximately 82% of European hospitals with stewardship programmes participating in this survey having an IV to oral switch programme [35].

The UK, Belgium, Austria and Germany all have antimicrobial stewardship initiatives that incorporate IV to oral switch therapy programmes. For example, the Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infections in England initiated the 'Start Smart—then Focus' programme. This national antimicrobial stewardship programme contains an IV to oral switch component (Fig. 1) [26]. This initiative focuses on a review of antimicrobial therapy 48 h after treatment initiation. The best practice standard for IV to oral switch therapy is that IV antibiotics be switched to oral therapy within 24 h of the patient meeting local switch criteria. Recommendations are to audit IV to oral switch programmes annually or monitor the consumption of IV compared with oral antimicrobial therapy.

The Scottish Antimicrobial Prescribing Group (SAPG) is responsible for implementation of the Scottish Management of

Antimicrobial Resistance Action Plan (ScotMARAP) [36]. The ScotMARAP includes IV to oral switch guidance for patients receiving empirical antimicrobial therapy.

Sequential IV to oral therapy is also a component of the majority of antimicrobial stewardship programmes supported by the Belgian Antibiotic Policy Coordination Committee (BAPCOC) [37]. The BAPCOC supports the development of antibiotic management teams through policy guidance and federal funding for antibiotic managers. Sequential IV to oral therapy guidelines are used by approximately 79% of the antibiotic management teams.

Intravenous to oral switch programmes are core activities of antimicrobial stewardship programmes in Austria and Germany [38]. The quality indicator states that hospitals should have written recommendations for parenteral-to-oral switch antimicrobial therapy available and that they are updated every 2 years. Similarly, a quality indicator was developed and proposed for assessing the appropriate IV to oral switch of bioavailable antibiotics. This is believed to be a feasible and clinically relevant approach to measuring the implementation of the interventions and may provide the quality improvement leverage within healthcare systems [14].

Lastly, to ensure greater consistency of stewardship indicators, the Transatlantic Taskforce on Antimicrobial Resistance [TAT-FAR] group has developed through a formal Delphi process structural and process indicators for stewardship; the availability of IV to oral switch guidance is a key supplementary indicator (D. Nathwani, personal communication). Such international guidance again supports the value of this stewardship strategy.

### Hospital-specific programmes


Numerous examples of hospital-specific ES and ED programmes are available in the published medical literature [7,9,12–24]. Most programmes evaluate a patient's ability to take oral therapy 2–3 days after initiation of IV therapy (Fig. 2). Although different approaches to programme implementation are used, most of these programmes through the use of policies, treatment guidelines, surveillance data, educational resources, targeted intervention and audit aim to reduce the number of IV inpatient antibiotic days. Successful programmes typically include immediate feedback, which is directed to the physician-in-charge and contain patient-specific, clear, unambiguous advice [7].

## Barriers to implementation

### Country level

Several barriers to implementation of ES and ED programmes at a national level are described in the medical literature. The inclusion of an IV to oral switch programme in a national antimicrobial stewardship initiative does not guarantee the





**FIG. 1.** Antimicrobial Stewardship in Secondary Care, Antimicrobial Stewardship Algorithm [26].

acceptance or success of the programme at a hospital level [39]. Evidence from England suggests that acceptance of nationally or centrally developed programmes is slow. Prescribing appears to be influenced by the cultural beliefs of the patient and the prescriber, patient demand, socio-economic factors, and clinical autonomy, not national guidelines [40,41]. To improve uptake of national guidelines, recommendations are to develop consensus documents through collaboration of key stakeholders at the national level and disseminate these recommendations at a local level through the identification and professional development of local leaders [42].

#### Unit/hospital level

Barriers to ES and ED at a unit/hospital level include staffing time constraints, staffing changes and prescribing etiquette [43,44]. Reassessment of antimicrobial therapy after 48–72 h of treatment is often neglected because of time constraints and changes in staffing [19]. Information on why the antimicrobial was started and the goal of therapy may not be communicated among clinical teams resulting in the unnecessary continuation of antibiotic therapy including unnecessary IV therapy. In many


institutions, prescribing etiquette, or the reluctance of junior medical staff members to change the prescribing habits of more senior staff members, determines or influences treatment patterns [43]. Changes to antibiotic regimens are often made by more senior medical staff, who typically review patient medical charts less frequently than junior staff members.

#### Prescriber level

Prescribers are often hesitant to modify an apparently efficacious empirical therapy, especially if there is no direct oral equivalent for the IV formulation [45]. To overcome this barrier, precise recommendations should be offered when requesting a change from an IV antibiotic with no direct oral equivalent formulation. Potentially, ES and ED programmes may benefit by administration of IV antibiotics with highly bioavailable oral formulations, by offering precise guidelines regarding which oral antibiotics can be substituted for IV antibiotics or be used to treat specific conditions, or by providing an infectious disease consult [46]. Other prescriber-specific barriers identified include time constraints, rapid rotation of physicians in charge of patients, and the belief that IV therapy is superior to oral therapy [22,44].

# INTRAVENOUS ANTIBIOTICS

## HAS YOUR PATIENT BEEN ON IV ANTIMICROBIALS FOR MORE THAN 48 HOURS?



**CONSIDER THE 5 ANTIMICROBIAL DECISION OPTIONS**

**STOP**  
IF NO EVIDENCE OF INFECTION

**SWITCH**  
IV-TO-ORAL

**CHANGE**  
TO NARROW SPECTRUM ANTIMICROBIAL AGENT

**CONTINUE**  
AND REVIEW AGAIN AT 72 HOURS

**OPAT**  
OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY

## CHANGE JABS TO TABS

**IV THERAPY INDICATED**

- Severe sepsis/failure to respond to existing IV therapy/deteriorating clinical condition
- Bacteraemia
- Febrile neutropenia
- Deep abscess/tissue infection
- Meningitis
- Encephalitis
- Brain abscess
- Osteomyelitis/septic arthritis
- Endocarditis
- Pyelonephritis
- Prosthetic device infection
- Cystic fibrosis-related infection
- Specific Microbiology/ID/AMT advice

**EARLY IV-TO-ORAL SWITCH (IVOS) CAN:**

- Reduce drug costs
- Reduce workloads
- Reduce patient stay
- Reduce hospital-related morbidity
- Increase patient satisfaction

For advice, please refer to: UHD Antimicrobial Guidelines (Intranet) Microbiology Duty Room (26066) Infectious Diseases (Switchboard)

**IVOS SWITCH**

Switch IV-to-oral as soon as appropriate

- Temperature <38°C for 48 hours and no unexplained tachycardia
- Patient clinically improved and no longer any indications for IV therapy
- Oral food/fluids tolerated and there is no reason to suspect oral absorption may be poor
- Suitable oral alternative
- White cell count and CRP improving (if being monitored)

**ANTIMICROBIAL MANAGEMENT TEAM**  
NHS Lothian - University Hospitals Division

**FIG. 2.** Example of intravenous to oral switch policy [9]. Reproduced from McCallum et al. [9] with permission from the authors.

## Conclusions

The benefits of ES and ED programmes to patients and providers are many. Patient benefits include increased comfort and mobility, decreased risk of IV-line related adverse effects, and improved recovery times. Provider benefits include decreased IV preparation time, potential for reduced hospital length of stays, and decreased antimicrobial purchasing and administration costs. Therefore, ES and ED programmes have the potential to offer improved quality of care at reduced total cost, thereby providing a powerful and persuasive argument for adoption and implementation [47].

Antimicrobial stewardship programmes should incorporate not only ES and ED initiatives that focus on optimizing drug regimens but additional initiatives that focus on minimizing drug resistance.

Recommendations for implementing ES and ED programmes in hospitals are shown in Table 4. It is important for hospitals to engage key stakeholders early in the planning process, in order to identify and respond to potential barriers to adherence. Multi-pronged approaches that provide clear and explicit feedback are the most likely to succeed in altering prescribing behaviour. Measuring and feeding back the benefits of these programmes will also be instrumental in generating continued buy-in from practitioners and administrators [48].



**TABLE 4. Recommendations for implementing early switch/early discharge programmes for antibiotics**

- Identify the size of the problem locally and opportunities for early switch/early discharge through audit and harness local support from clinicians and administrators
- Outline an evidence-based plan of implementation with measurable criteria for success for implementation
- Engage a multidisciplinary team in the design of the programme, including key stakeholders from the clinical service and infection specialists (e.g. Infectious Diseases, Microbiology, and Pharmacy and Nursing departments). Identify clinician champions where possible
- Use multiple intervention tools to promote good antibiotic prescribing practices, including educational activities and materials, audit and feedback, and reminders. Ensure these tools are tested/piloted before spread to all parts of the hospital; prevent duplication of process—embed or integrate into similar existing work such as review of need for peripheral venous cannulae
- Provide prescribers with timely and regular feedback that is clear and directive, and deliver specific recommendations for improved prescribing (e.g. antibiotic dose, route and frequency)
- Evaluate the programme performance regularly to demonstrate its value and benefits to key stakeholders

## Transparency declaration

D. Nathwani has received lecture fees, travel support for attending meetings and fees for advisory boards from Astellas, Astra-Zeneca, Bayer, Cubist, Durata, Medicines Company, Biomerieux & Pfizer Inc. He has received no fees in relation to this manuscript. W. Lawson has received travel support for attending meetings and fees for advisory boards from Astellas and Pfizer. M. Dryden has received honoraria for speaking and for serving on advisory boards from AstraZeneca, Pfizer, Novartis, Bayer and Janssen-Cilag. J. Stephens, S. Corman, and C. Solem are employees of Pharmerit International, who were paid consultants to Pfizer in connection with this manuscript. J. Li, C. Charbonneau, N. Baillon-Plot, and S. Haider are employees of Pfizer. C. Eckmann has received lecture fees, travel support for attending meetings and fees for advisory boards from Bayer, AstraZeneca, Cubist, Durata and Pfizer.

## Acknowledgement

The authors wish to thank Beth Leshar, PharmD, BCPS for medical writing support.

## References

- [1] European Center for Disease Prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. 2013. <http://www.ecdc.europa.eu/en/publications/publications/healthcare-associated-infections-antimicrobial-use-pps.pdf>.
- [2] Eckmann C, Lawson W, Nathwani D, Solem CT, Stephens JM, Macahilig C, et al. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to methicillin-resistant *Staphylococcus aureus*: a plea for implementation of early switch and early discharge criteria. *Int J Antimicrob Agents* 2014;44:56–64.
- [3] Itani K, Sorensen S, Stokes M, Shalbaya A, McKinnon PS. A regional comparison of resource utilization in patients with methicillin-resistant *Staphylococcus aureus* (MRSA) complicated skin and soft tissue infections (cSSTI) treated with linezolid vs vancomycin. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009. San Francisco, CA.
- [4] Nathwani D. Developments in outpatient parenteral antimicrobial therapy (OPAT) for gram-positive infections in Europe, and the potential impact of daptomycin. *J Antimicrob Chemother* 2009;64:447–53.
- [5] Dryden M, Saeed K, Townsend R, Winnard C, Bourne S, Parker N, et al. Antibiotic stewardship and early discharge from hospital: impact of a structured approach to antimicrobial management. *J Antimicrob Chemother* 2012;67:2289–96.
- [6] MacKenzie M, Rae N, Nathwani D. Outcomes from global adult outpatient parenteral antimicrobial therapy programmes: a review of the last decade. *Int J Antimicrob Agents* 2014;43:7–16.
- [7] Sevinc F, Prins JM, Koopmans RP, Langendijk PN, Bossuyt PM, Dankert J, et al. Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital. *J Antimicrob Chemother* 1999;43:601–6.
- [8] Dellit TH, Owens RC, McGowan Jr JE, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. *Clin Infect Dis* 2007;44:159–77.
- [9] McCallum AD, Sutherland RK, Mackintosh CL. Improving antimicrobial prescribing: implementation of an antimicrobial i.v.-to-oral switch policy. *J R Coll Physicians Edinb* 2013;43:294–300.
- [10] Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. *Thorax* 2009;64(Suppl. 3). iii:1–55.
- [11] Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis* 2007;44(Suppl. 2):S27–72.
- [12] Ahkee S, Smith S, Newman D, Ritter W, Burke J, Ramirez JA. Early switch from intravenous to oral antibiotics in hospitalized patients with infections: a 6-month prospective study. *Pharmacotherapy* 1997;17:569–75.
- [13] Bal AM, Shankland GS, Scott G, Imtiaz T, Macaulay R, McGill M. Antifungal step-down therapy based on hospital intravenous to oral switch policy and susceptibility testing in adult patients with candidaemia: a single centre experience. *Int J Clin Pract* 2014;68:20–7.
- [14] Buyle FM, Metz-Gercek S, Mechtler R, Kern WV, Robays H, Vogelaers D, et al. Prospective multicentre feasibility study of a quality of care indicator for intravenous to oral switch therapy with highly bioavailable antibiotics. *J Antimicrob Chemother* 2012;67:2043–6.
- [15] Conly JM, Stiver HG, Weiss KA, Becker DL, Rosner AJ, Miller E. A retrospective analysis of practice patterns in the treatment of methicillin-resistant *Staphylococcus aureus* skin and soft tissue infections at three Canadian tertiary care centres. *Can J Infect Dis* 2003;14:315–21.
- [16] Desai M, Franklin BD, Holmes AH, Trust S, Richards M, Jacklin A, et al. A new approach to treatment of resistant gram-positive infections: potential impact of targeted iv to oral switch on length of stay. *BMC Infect Dis* 2006;6:694.

- [17] Dunn K, O'Reilly A, Silke B, Rogers T, Bergin C. Implementing a pharmacist-led sequential antimicrobial therapy strategy: a controlled before-and-after study. *Int J Clin Pharm* 2011;33:208–14.
- [18] Laing RB, Mackenzie AR, Shaw H, Gould IM, Douglas JG. The effect of intravenous-to-oral switch guidelines on the use of parenteral antimicrobials in medical wards. *J Antimicrob Chemother* 1998;42: 107–11.
- [19] Mertz D, Koller M, Haller P, Lampert ML, Plagge H, Hug B, et al. Outcomes of early switching from intravenous to oral antibiotics on medical wards. *J Antimicrob Chemother* 2009;64:188–99.
- [20] Parodi S, Rhew DC, Goetz MB. Early switch and early discharge opportunities in intravenous vancomycin treatment of suspected methicillin-resistant *Staphylococcal* species infections. *J Manag Care Pharm* 2003;9:317–26.
- [21] van Niekerk AC, Venter DJ, Boschmans SA. Implementation of intravenous to oral antibiotic switch therapy guidelines in the general medical wards of a tertiary-level hospital in South Africa. *J Antimicrob Chemother* 2012;67:756–62.
- [22] Vanstraelen K, Verhaegen J, Peetermans WE, Willems L, Spriet I. Stimulation of the i.v. to oral switch of bioavailable drugs by phone calls in a Belgian tertiary care hospital. *Acta Clin Belg* 2013;68:179–82.
- [23] Vogtlander NP, Van Kasteren ME, Natsch S, Kullberg BJ, Hekster YA, Van Der Meer JW. Improving the process of antibiotic therapy in daily practice: interventions to optimize timing, dosage adjustment to renal function, and switch therapy. *Arch Intern Med* 2004;164:1206–12.
- [24] Waagsbo B, Sundoy A, Paulsen EQ. Reduction of unnecessary i.v. antibiotic days using general criteria for antibiotic switch. *Scand J Infect Dis* 2008;40:468–73.
- [25] Nathwani D, Eckmann C, Lawson W, Stephens JM, Macahilig C, Solem CT, et al. Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant *Staphylococcus aureus* complicated skin and soft tissue infections. *Clin Microbiol Infect* 2014;20:993–1000.
- [26] Department of Health Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) Antimicrobial Stewardship Subgroup. Antimicrobial stewardship: “Start smart – then focus”; guidance for antimicrobial stewardship in hospitals (England). 2011. [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/215308/dh\\_131181.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/215308/dh_131181.pdf).
- [27] Smyth E, Cunney R, Bergin C, Lambert J, O'Reilly A, Philbin M, et al. Guidelines for antimicrobial stewardship in hospitals in Ireland, SARI hospital antimicrobial stewardship working group 2009. Dublin: HSE Health Protection Surveillance Centre; 2009.
- [28] Goff DA, Bauer KA, Reed EE, Stevenson KB, Taylor JJ, West JE. Is the “low-hanging fruit” worth picking for antimicrobial stewardship programs? *Clin Infect Dis* 2012;55:587–92.
- [29] Carratala J, Garcia-Vidal C, Ortega L, Fernandez-Sabe N, Clemente M, Albero G, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. *Arch Intern Med* 2012;172:922–8.
- [30] van Zanten AR, Engelfriet PM, van Dillen K, van Veen M, Nuijten MJ, Polderman KH. Importance of nondrug costs of intravenous antibiotic therapy. *Crit Care* 2003;7:R184–90.
- [31] Gray A, Dryden M, Charos A. Antibiotic management and early discharge from hospital: an economic analysis. *J Antimicrob Chemother* 2012;67:2297–302.
- [32] Bamford KB, Desai M, Aruede MJ, Lawson W, Jacklin A, Franklin BD. Patients' views and experience of intravenous and oral antimicrobial therapy: room for change. *Injury* 2011;42(Suppl. 5):S24–7.
- [33] Manuel O, Burnand B, Bady P, Kammerlander R, Vansantvoet M, Francioli P, et al. Impact of standardised review of intravenous antibiotic therapy 72 hours after prescription in two internal medicine wards. *J Hosp Infect* 2010;74:326–31.
- [34] Vouloumanou EK, Rafailidis PI, Kazantzi MS, Athanasiou S, Falagas ME. Early switch to oral versus intravenous antimicrobial treatment for hospitalized patients with acute pyelonephritis: a systematic review of randomized controlled trials. *Curr Med Res Opin* 2008;24:3423–34.
- [35] Howard P, Pulcini C, Levy Hara G, West RM, Gould IM, Harbarth S, et al. An international cross-sectional survey of antimicrobial stewardship programmes in hospitals. *J Antimicrob Chemother* 2015;70: 1245–55.
- [36] Nathwani D, Sneddon J, Malcolm W, Wiuff C, Patton A, Hurding S, et al. Scottish antimicrobial prescribing group (SAPG): development and impact of the Scottish National Antimicrobial Stewardship Programme. *Int J Antimicrob Agents* 2011;38:16–26.
- [37] Van Gastel E, Costers M, Peetermans WE, Struelens MJ, Hospital Medicine Working Group of the Belgian Antibiotic Policy Coordination Committee. Nationwide implementation of antibiotic management teams in Belgian hospitals: a self-reporting survey. *J Antimicrob Chemother* 2010;65:576–80.
- [38] Thern J, de With K, Strauss R, Steib-Bauert M, Weber N, Kern WV. Selection of hospital antimicrobial prescribing quality indicators: a consensus among German antibiotic stewardship (ABS) networkers. *Infection* 2014;42:351–62.
- [39] Ashiru-Oredope D, Hopkins S, English Surveillance Programme for Antimicrobial Utilization Resistance Oversight Group. Antimicrobial stewardship: English surveillance programme for antimicrobial utilization and resistance (EUSPAR). *J Antimicrob Chemother* 2013;68: 2421–3.
- [40] Mason A. New medicines in primary care: a review of influences on general practitioner prescribing. *J Clin Pharm Ther* 2008;33:1–10.
- [41] Hulscher ME, Grol RP, van der Meer JW. Antibiotic prescribing in hospitals: a social and behavioural scientific approach. *Lancet Infect Dis* 2010;10:167–75.
- [42] Nathwani D, Sneddon J, Patton A, Malcolm W. Antimicrobial stewardship in Scotland: impact of a national programme. *Antimicrob Resist Infect Control* 2012;1:7.
- [43] Charani E, Castro-Sanchez E, Sevdalis N, Kyratsis Y, Drumright L, Shah N, et al. Understanding the determinants of antimicrobial prescribing within hospitals: the role of “prescribing etiquette”. *Clin Infect Dis* 2013;57:188–96.
- [44] Engel MF, Postma DF, Hulscher ME, van Berkhout FT, Emmelot-Vonk MH, Sankatsing S, et al. Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with community-acquired pneumonia. *Eur Respir J* 2013;41:123–30.
- [45] Schouten JA, Hulscher ME, Natsch S, Kullberg BJ, van der Meer JW, Grol RP. Barriers to optimal antibiotic use for community-acquired pneumonia at hospitals: a qualitative study. *Qual Saf Health Care* 2007;16:143–9.
- [46] Duncan RA. Controlling use of antimicrobial agents. *Infect Control Hosp Epidemiol* 1997;18:260–6.
- [47] Chassin MR, Galvin RW. The urgent need to improve health care quality. Institute of Medicine national roundtable on health care quality. *JAMA* 1998;280:1000–5.
- [48] Ivers NM, Sales A, Colquhoun H, Michie S, Foy R, Francis JJ, et al. No more ‘business as usual’ with audit and feedback interventions: towards an agenda for a reinvigorated intervention. *Implement Sci* 2014;9:14.